Affimed NV (LTS:0HL9)
$ 6.1 -0.37 (-5.72%) Market Cap: 93.50 Mil Enterprise Value: 35.19 Mil PE Ratio: 0 PB Ratio: 1.46 GF Score: 42/100

Affimed NV at Citi Immuno-Oncology Summit (Virtual) Transcript

Feb 17, 2022 / 07:30PM GMT
Release Date Price: $44 (-1.31%)
Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

Okay. Great. Welcome back everyone to Citi's IO Summit for 2022. I'm Yigal Nochomovitz, one of the biotech analysts here at Citi. I think most of you know me. If you do have questions for the management team, you can just e-mail me, [email protected] and I will relay those questions to the management team.

So with that, it's my pleasure to introduce from Affimed, the CEO, Adi Hoess as well as the CMO, Andreas Harstrick. I welcome both of you. So Adi, maybe as a starting point, it would be great, if you could just do a general introduction to the company for those that are less familiar with the story, just explaining how the innate cell engager platform is differentiated from competing approaches in the NK cell engager space. Yigal, thanks a lot for the introduction. Just sorry about that.

Adi Hoess
Affimed N.V. - CEO, MD & Member of Management Board

So I'm also happy to welcome everybody joining this video conference. Quite excited to be able to present to you about

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot